NEW POTENT SYNTHETIC OPIOID—N-DESETHYL ISONITITAZENE—PROLIFERATING AMONG RECREATIONAL DRUG SUPPLY IN USA

PURPOSE: The objective of this announcement is to notify public health and safety, law enforcement, first responders, clinicians, medical examiners and coroners, forensic and clinical laboratory personnel, and all other related communities about new information surrounding the emergent synthetic opioid N-desethyl isonitizene.

BACKGROUND: Synthetic opioids (e.g., fentanyl, fentanyl analogues) are chemically manufactured drugs, often having unknown potency and adverse effects or health risks. Synthetic opioids are frequently mixed with more traditional opioids (e.g., heroin) and other drugs in unregulated drug markets creating additional risk and danger for people who use recreational drugs. Synthetic opioids may be distributed in powder or tablet form. In the United States (USA), an alarming increase in the number of deaths linked to synthetic opioid use has been reported. Primary adverse effects associated with synthetic opioid use are sedation and respiratory depression, leading to death.

SUMMARY: N-Desethyl isonitizene is a new synthetic opioid bearing structural resemblance to isonitizene and recently emergent nitazene analogues. N-Desethyl isonitizene is dissimilar in chemical structure to fentanyl, the synthetic opioid most commonly encountered, but this subclass of new opioids has been proliferating in the wake of the scheduling of fentanyl analogues. N-Desethyl isonitizene is a known metabolite of isonitizene; however, it has now emerged as a primary drug in its own right. Most nitazene analogues encountered retain opioid receptor activity and potency similar to or greater than fentanyl. In vitro pharmacological data show that N-desethyl isonitizene is an active opioid agonist and is approximately 20x more potent than fentanyl. In December 2022, N-desethyl isonitizene was first reported by NPS Discovery (Florida); however, first identifications were observed as early as September 2022. To date, seven drug material samples (“dope” powders) collected from the Philadelphia drug supply have tested positive for N-desethyl isonitizene. In December 2022, the Philadelphia Department of Public Health issued an alert regarding the discovery of this new nitazene analogue in the city’s drug supply. The toxicity of N-desethyl isonitizene has not been examined or reported but recent association with overdoses among people who use drugs leads professionals to believe this synthetic opioid has the potential to cause harm and is of high public health concern.

TIMELINE — N-DESETHYL ISONITITAZENE ...

- Identified in urine samples from a drug treatment program (PA).
- Identified in oral fluid samples collected from people who use drugs (PA).
- Identified in a counterfeit “A215” (oxycodeone) round blue tablet (FL).
- Identified in “dope” samples alongside fentanyl, xylazine, and bromazolam (PA).
- Continues to be identified in “dope” samples among Philadelphia drug supply (PA).

2022
September
October
November
December
2023
January

“DOPE” SAMPLES CONTAINING N-DESETHYL ISONITITAZENE

LOCATION: Philadelphia, PA, USA
NUMBER OF SAMPLES: 7

CONTENTS (PURITY RANGE):
- Xylazine (49% to 76%)
- Fentanyl (1.3% to 5.3%)
- N-Desethyl Isonitizene (0.05% to 0.4%)
- Bromazolam (trace to 2.5%)
- Flurbiprofen (trace)
- Flurbiprofen (trace)
- Paro-Fluorofentanyl (trace)

RECOMMENDATIONS FOR CLINICIANS
- Become familiar with the signs and symptoms associated with synthetic opioid use (e.g., sedation, respiratory depression).
- Naloxone should be administered to reverse critical respiratory depression and repeated naloxone administration may be necessary. Be aware that clinical conditions may change rapidly and unpredictably after naloxone administration due to other drugs on board or precipitation of withdrawal, which may be more severe with faster onset.
- Be mindful that drugs have limited quality control, containing unclarified substances that impact clinical effects or findings.
- Counsel about the harms and dangers of synthetic opioid products and other drugs.

RECOMMENDATIONS FOR PUBLIC HEALTH
- Implement surveillance for rapid identification of drug overdose outbreaks. Engage local poison centers and clinicians to assist with treatment of affected patients.
- Track and monitor geographical drug distribution and trends. Track demographics and known risk factors.
- Raise awareness about the risks, harms, and dangers associated with opioid use.
- Make naloxone available to people who use drugs. Notify personnel that naloxone remains effective at reversing opioid overdoses caused by nitazene analogues.
- Be aware that fentanyl test strips are not effective at detecting nitazene analogues.

RECOMMENDATIONS FOR LABORATORIES
- Utilize analytical data available publicly for the identification of N-desethyl isonitazene if a reference standard is not immediately available.
- Utilize previously developed non-targeted testing protocols or develop sensitive and up-to-date testing procedures for synthetic opioids and novel drugs.
- Prioritize analytical testing of drug materials obtained from drug overdose scenes during death investigations.
- Share data on synthetic opioid drug seizures with local health departments, medical examiners, coroners, and related communities.

RECOMMENDATIONS FOR MEDICAL EXAMINERS & CORONERS
- Test for new synthetic opioids and their biomarkers (if known) in suspected opioid overdose cases.
- Be aware that ELISA screening for synthetic opioids is not specific or specialized for the newest generations of drugs — Mass spectrometry-based screening is necessary.
- Be aware that concentrations of synthetic opioids in biological specimens can vary and GC-MS sensitivity may not be adequate.
- Consult with forensic toxicologists about novel opioid activity, potency, and association with overdose and/or death.

ACKNOWLEDGMENTS: This report was prepared by Ane J. Wistuba, Jennifer Sheehy, Daniel Telepa da Silva, Amanda LA. Mah, Joshua DeBord, Sara E. Walton, and Barry K. Logan at the Center for Forensic Science Research and Education (CFSE) at the Freebie (Renes) Family Foundation. The authors acknowledge scientists, epidemiologists, and staff at the CFSE and PIRM for their involvements and contributions. For more information about CFSE’s programs and reports, please contact NPS Discovery at pirm@npsdiscovery.org or visit our website at www.npsdiscovery.org.

FUNDING: Our drug checking program is funded by the Centers for Disease Control and Prevention (CDC) through an Overdose Data to Action grant awarded to the City of Philadelphia NPS Discovery at the CFSE. It is supported in part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (2023-CF-0051). The contents, findings, conclusions and/or recommendations expressed in this publication are those of the authors and do not necessarily represent the official position or policies of the CDC, DOJ, or other federal, state, local, or private agencies.